Following the initial impact of the COVID-19 pandemic, the US market for TEO devices will expand at a moderate rate. Market growth will be driven by continual product innovations and the approval of new treatment indications, which will support market expansion throughout the forecast period.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for TEO devices in the US across a 10-year period.

The US TEO device market will be impacted by the COVID-19 pandemic in the short term.

What factors will contribute to the market decline?

To what degree will the pandemic affect different procedures and devices?

How soon will procedure volumes, sales, and revenues recover over the forecast period?

Flow-diverting devices are contributing to growth in the neurovascular embolization market.

What devices were recently introduced into the market?

How will the introduction of new flow-diverting devices affect the competitive dynamics of the segment that was previously monopolized by a single competitor?

How will adoption of flow-diverting devices impact the neurovascular embolization coil and coiling-assist device markets?

The embolization particle market has seen many mergers and acquisitions.

What makes this market so dynamic and lucrative?

What competitive strategies are companies following when engaging in mergers and acquisitions in this space?

How will these mergers and acquisitions shape competitive dynamics in the US TEO embolization particle markets?

The PV plug market is dynamic, with new companies and products entering this space.

How has the competitive landscape changed with the emergence of new competitors and products?

How will the growing PV plug market impact the PV embolization coil market?

Table of contents

  • Transcatheter Embolization And Occlusion Devices - Market Insights - United States

Author(s): Xi Chen, PhD

Xi Chen is a manager on the Medtech Insights team at Decision Resources Group and currently serves as the in-house expert in general surgery, gastroenterology, ENT, and robotic surgery markets. Xi has been instrumental in improving the team’s market modeling capabilities and has also helped broaden the team’s expertise in leveraging medical claims and hospital purchase order data to perform market sizing and competitive analysis. Xi has been featured in several industry publications, particularly for his expertise in the robotic surgery market. Xi holds a Ph.D. in Biomedical Engineering from the University of Toronto.